We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Veeva sees growth from Vault CRM migration, AI tools and expanding Clinical Development Cloud.
Strategic deals include Boehringers CRM migration and a Walgreens partnership for clinical research.
Q1 fiscal 2026 earnings and revenues beat estimates, led by subscription and professional services.
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-quarter fiscal 2026 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern.
This Zacks Rank #2 (Buy) company’s shares have risen 31.7% in the year-to-date period compared with 19.9% growth of the industry. The S&P 500 composite has declined 8.5% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $46.1 billion. The company anticipates 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 10%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Robust Product Portfolio: Veeva Systems continues to drive the migration to its next-gen Vault CRM, with 20 new customers adopting the solution, particularly small and mid-sized biotech firms preparing for commercial launches. The company expects most top 20 pharma firms to make migration decisions by fiscal 2026, ahead of the 2030 sunset of the legacy CRM.
Veeva Systems has introduced AI-driven innovations like CRM Voice Control, CRM Bot and MLR Bot to enhance efficiency, compliance and automation. Meanwhile, VEEV’s Clinical Development Cloud sees growing adoption, with 17 of the top 20 pharma companies using its CTMS and a ninth committing to an EDC solution. Investments in RTSM and eCOA further expand its market opportunities.
Veeva Systems’ Data Cloud solutions — Compass, OpenData, Link and the new Pulse — are gaining momentum. Compass supports more than 100 brands and Pulse secured its first seven-figure deal to enhance pharma segmentation and targeting. While enterprise-wide licensing is still in the early stages, larger contracts are expected. Veeva Systems is also expanding its Safety suite, offering a fully cloud-based solution for signal detection, adverse event reporting and regulatory compliance, with automated updates and seamless clinical integration.
Strategic Deals: The company has secured several key deals in recent months, including Boehringer Ingelheim's commitment to migrate to Veeva Vault CRM, expanding its use of Veeva Commercial Cloud and Development Cloud. Additionally, ACTO joined the Veeva AI Partner Program to enhance generative AI capabilities for field representatives in life sciences. In October, Veeva Systems and Walgreens Boots Alliance announced a long-term partnership to leverage the former’s Data Cloud and Clinical Platform, aiming to improve patient outcomes by connecting the latter’s community locations with diverse patient populations for easier clinical research access.
Strong Q1 Results: Veeva Systems exited the first quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat their respective consensus estimate. The uptick in the overall top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. Revenue uptick in Professional services and others also bodes well.
Veeva Systems also announced a significant step forward in its artificial intelligence strategy with the introduction of Veeva AI. Set for an initial release in December 2025, Veeva AI will embed intelligent automation and productivity tools directly into its applications and Vault Platform. Features will include AI Agents and user-defined AI Shortcuts tailored to specific workflows in clinical and commercial functions. This initiative complements other key developments like the Veeva Direct Data API and the Veeva AI Partner Program, which are collectively aimed at transforming operational efficiency across life sciences.
Factor That May Offset the Gains of VEEV
Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. General and administrative expenses for the first quarter of fiscal 2026 increased 12.3% year over year. Management expects sales and marketing expenses to increase in fiscal 2026, primarily due to employee-related expenses as the company raises its headcount to support sales and marketing efforts associated with product offerings and the continued expansion of sales capacity across all solutions.
In the fiscal first quarter, the total operating expenses increased 9.4% year over year. Veeva Systems expects operating expenses to increase in fiscal 2026, primarily due to employee compensation-related costs.
Estimate Trend
Veeva Systems is witnessing a positive estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for fiscal 2026 earnings per share (EPS) has moved 3 cents north to $7.64.
The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues is pegged at $767.6 million, indicating a 13.5% improvement from the year-ago quarter’s reported number. The EPS estimate for the second quarter of fiscal 2026 is pinned at $1.90, implying a 17.3% improvement year over year.
Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Revenues of $603.3 million outpaced the consensus mark by 11.5%. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million beat the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion beat the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
Key Takeaways
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-quarter fiscal 2026 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern.
This Zacks Rank #2 (Buy) company’s shares have risen 31.7% in the year-to-date period compared with 19.9% growth of the industry. The S&P 500 composite has declined 8.5% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $46.1 billion. The company anticipates 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 10%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Robust Product Portfolio: Veeva Systems continues to drive the migration to its next-gen Vault CRM, with 20 new customers adopting the solution, particularly small and mid-sized biotech firms preparing for commercial launches. The company expects most top 20 pharma firms to make migration decisions by fiscal 2026, ahead of the 2030 sunset of the legacy CRM.
Veeva Systems has introduced AI-driven innovations like CRM Voice Control, CRM Bot and MLR Bot to enhance efficiency, compliance and automation. Meanwhile, VEEV’s Clinical Development Cloud sees growing adoption, with 17 of the top 20 pharma companies using its CTMS and a ninth committing to an EDC solution. Investments in RTSM and eCOA further expand its market opportunities.
Veeva Systems’ Data Cloud solutions — Compass, OpenData, Link and the new Pulse — are gaining momentum. Compass supports more than 100 brands and Pulse secured its first seven-figure deal to enhance pharma segmentation and targeting. While enterprise-wide licensing is still in the early stages, larger contracts are expected. Veeva Systems is also expanding its Safety suite, offering a fully cloud-based solution for signal detection, adverse event reporting and regulatory compliance, with automated updates and seamless clinical integration.
Strategic Deals: The company has secured several key deals in recent months, including Boehringer Ingelheim's commitment to migrate to Veeva Vault CRM, expanding its use of Veeva Commercial Cloud and Development Cloud. Additionally, ACTO joined the Veeva AI Partner Program to enhance generative AI capabilities for field representatives in life sciences. In October, Veeva Systems and Walgreens Boots Alliance announced a long-term partnership to leverage the former’s Data Cloud and Clinical Platform, aiming to improve patient outcomes by connecting the latter’s community locations with diverse patient populations for easier clinical research access.
Strong Q1 Results: Veeva Systems exited the first quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat their respective consensus estimate. The uptick in the overall top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. Revenue uptick in Professional services and others also bodes well.
Veeva Systems also announced a significant step forward in its artificial intelligence strategy with the introduction of Veeva AI. Set for an initial release in December 2025, Veeva AI will embed intelligent automation and productivity tools directly into its applications and Vault Platform. Features will include AI Agents and user-defined AI Shortcuts tailored to specific workflows in clinical and commercial functions. This initiative complements other key developments like the Veeva Direct Data API and the Veeva AI Partner Program, which are collectively aimed at transforming operational efficiency across life sciences.
Factor That May Offset the Gains of VEEV
Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. General and administrative expenses for the first quarter of fiscal 2026 increased 12.3% year over year. Management expects sales and marketing expenses to increase in fiscal 2026, primarily due to employee-related expenses as the company raises its headcount to support sales and marketing efforts associated with product offerings and the continued expansion of sales capacity across all solutions.
In the fiscal first quarter, the total operating expenses increased 9.4% year over year. Veeva Systems expects operating expenses to increase in fiscal 2026, primarily due to employee compensation-related costs.
Estimate Trend
Veeva Systems is witnessing a positive estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for fiscal 2026 earnings per share (EPS) has moved 3 cents north to $7.64.
The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues is pegged at $767.6 million, indicating a 13.5% improvement from the year-ago quarter’s reported number. The EPS estimate for the second quarter of fiscal 2026 is pinned at $1.90, implying a 17.3% improvement year over year.
Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $603.3 million outpaced the consensus mark by 11.5%. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million beat the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion beat the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.